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Abstract 20 
Proton-pump inhibitor (PPI) products based on enteric coated multiparticulates are 21 
design to meet the needs of patients who cannot swallow tablets such as children and 22 
older adults. Enteric coated PPI preparations exhibit delays in in vivo absorption and 23 
onset of antisecretory effects, which is not reflected by the rapid in vitro dissolution in 24 
compendial pH 6.8 phosphate buffer commonly used for assessment of these 25 
products. A more representative and physiological medium, pH 6.8 mHanks 26 
bicarbonate buffer, was used in this study to evaluate the in vitro dissolution of enteric 27 
coated multiparticulate-based PPI products. Commercially available omeprazole, 28 
lansoprazole and esomeprazole products were subject to dissolution tests using USP-29 
II apparatus in pH 4.5 phosphate buffer saline for 45 minutes (acid stage) followed by 30 
pH 6.8 phosphate buffer or pH 6.8 mHanks bicarbonate buffer. In pH 6.8 phosphate 31 
buffer, all nine tested products displayed rapid and comparable dissolution profiles 32 
meeting the pharmacopeia requirements for delayed release preparations. In pH 6.8 33 
mHanks buffer, drug release was delayed and failed the pharmacopeia requirements 34 
from most enteric coated preparations. Despite that the same enteric polymer, 35 
methacrylic acid – ethyl acrylate copolymer (1:1), was applied to all commercial 36 
multiparticulate-based products, marked differences were observed between 37 
dissolution profiles of these preparations. The use of pH 6.8 physiological bicarbonate 38 
(mHanks) buffer can serve as a useful tool to provide realistic and discriminative in 39 
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vitro release assessment of enteric coated PPI preparations and to assist rational 40 
formulation development of these products.  41 
 42 
Key words: pellets,  dysphagia, modified release, physiological buffers, bicarbonate 43 
media, biorelevant dissolution  44 
 45 
1. Introduction 46 
 47 
Proton pump inhibitors (PPIs) are highly effective in gastric acid suppression and are 48 
increasingly used in the treatment of acid-related disorders such as gastroesophageal 49 
reflux disease and peptic ulcer disease (L. S. Welage, 2003). PPIs are acid-labile 50 
compounds; they rapidly degrade at pH levels below 4. Consequently, most PPI 51 
products are available as enteric coated (delayed release) dosage forms to protect the 52 
active drug in the stomach and release the drug in the small intestine. For patients who 53 
cannot swallow conventional tablets such as children and older patients, alternative 54 
PPI formulations have been developed including granules in sachets, pellet-enclosed 55 
capsules, orally dispersible tablets and MUPS (Multiple-Unit Pellet System) tablets. 56 
These formulations are based on the encapsulation of the active compound in enteric 57 
coated multiparticulates (granules, pellets, micropellets or microcapsules) of varying 58 
sizes.  59 
 60 
Enteric coatings applied to solid dosage forms employ polymers which contain 61 
carboxylic acid groups and exhibit pH-dependent dissolution. The dissociation of the 62 
enteric polymer and the resultant drug release from coated products in aqueous media 63 
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are affected not only by the pH of the media but also by their composition and other 64 
characteristics, such as the type of buffer species, ionic strength and buffer capacity 65 
(W. A. Chan et al., 2001; H. M. Fadda and A. W. Basit, 2005; V. C. Ibekwe et al., 66 
2006).  Commonly, the in vitro dissolution of enteric coated preparations is assessed 67 
in pH 6.8 phosphate buffer, albeit, this compendial buffer solution does not reflect the 68 
constitution of the luminal fluids of the small intestine and consequently gives poor 69 
prediction of the in vivo performance of these products. Phosphate content in the 70 
intestinal fluids is relatively neglectable and the principal buffer specie is bicarbonate. 71 
Efforts have been made to develop and utilise physiological solutions buffered by 72 
bicarbonate for dissolution testing of solid dosage forms coated with pH-responsive 73 
polymer systems (H. M. Fadda and A. W. Basit, 2005; H. M. Fadda et al., 2009; F. 74 
Liu et al., 2010). These media resemble more closely the physiological environment 75 
within the intestine and have been proven to provide better in vitro-in vivo 76 
correlations than conventional phosphate buffers.  77 
 78 
The enteric coatings applied to PPI products tend to hinder their absorption and delay 79 
the onset of antisecretory effect. It can take up to 4 hours for delayed-release PPIs to 80 
achieve maximum plasma concentration after oral ingestion (J. R. Horn and C. W. 81 
Howden, 2005). It was reported that immediate release omeprazole preparations 82 
stabilised using bicarbonate buffers provide faster absorption and onset of gastric acid 83 
suppression compared to delayed release omeprazole formulations (B. Hepburn and 84 
B. Goldlust, 2003).  In addition, rates of absorption are highly variable for different 85 
PPI preparations (J. R. Horn and C. W. Howden, 2005).  In vivo performances of 86 
enteric coated dosage forms are affected by their gastrointestinal transits especially 87 
gastric emptying times. Since enteric coated multiparticulates do not show typical in 88 
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vivo disintegration, neither conventional pharmacokinetic studies nor scintigraphies 89 
can fully evaluate their in vivo performances taking into account variations in gastric 90 
emptying. Pharmacoscintigraphy studies, a combination of scintigraphy with 91 
pharmacokinetic studies, are required to gain an understanding of the in vivo 92 
dissolution behaviour of these enteric coated products post-gastric emptying (I. R. 93 
Wilding et al., 2001). A predictive in vitro dissolution testing can serve as a useful 94 
tool during formulation development by providing discriminative in vitro data to 95 
guide the rational selection of desired formulation features. The aim of this study was 96 
to evaluate the in vitro dissolution of enteric coated multiparticulate PPI products in a 97 
pH 6.8 physiological bicarbonate (mHanks) buffer. This assessment was conducted on 98 
various commercially available delayed release PPI products intended for use in 99 
children and individuals with swallowing difficulties such as older patients.  100 
  101 
2. Materials and Methods  102 
 103 
2.1 Materials 104 
Omeprazole, lansoprazole and esomeprazole commercial products available in the UK 105 
that are based on enteric-coated multiparticulates were included in the study (Table 106 
1). Mepradec (omeprazole) was included as a tablet–enclosed capsule (10 mm oblong 107 
tablet) and as a comparison to multiparticulate-based products. These were obtained 108 
from respective producers (Table 1). Omeprazole, lansoprazole and esomeprazole 109 
standards were purchased from Sigma-Aldrich Co. Ltd., Dorset, UK. Salts for 110 
preparing buffer solutions were purchased from Sigma-Aldrich Co. Ltd., Dorset, UK. 111 
 112 
2.2 Particle size analysis 113 
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 114 
All multiparticulate-based products contain enteric-coated pellets or granules. The 115 
particle size of these multiparticulates was measured using either a laser diffraction 116 
particle size analyser or an analytical sieve shaker. Table 2 lists products analysed 117 
using each method. For pellet-enclosed capsules, contents of 10 capsules were 118 
emptied and weighted before the subsequent analysis. For sachets, oro-dispersible 119 
tablets and MUPS tablets, 10 tablets or contents of 10 sachets were dispersed in 0.1M 120 
HCl. The dispersed pellets were collected using filter papers and placed in an oven 121 
(40 °C) to dry for 6 hours. Dried pellets were weighed before subject to subsequent 122 
analysis.  123 
 124 
Laser diffraction particle size analysis was applied to products with a particle size 125 
smaller than 875µm. For each product tested under the laser diffraction particle size 126 
analysis, dry pellets (2g) were filled in the sample vials and were fed into a laser 127 
diffraction particle size analyser (Sympatec). Results were displayed as the median 128 
particle size (X50). Using the sieve method, dry pellets were put through a series of 129 
analytical test sieves mounted on an analytical sieve shaker (Copley Scientific, 130 
AS200). The opening diameters of the sieves were 2000, 1400, 1000, 710, 500, 355, 131 
250, 180, 125 and 90μm. The sieves were shaken for 10 minutes. Pellets remained on 132 
each sieve were collected and weighted.  133 
 134 
2.3 In vitro drug release 135 
 136 
Drug release from the commercial PPI products was evaluated using a USP II 137 
apparatus (Model PTWS, Pharmatest, Hainburg, Germany). The tests were conducted 138 
in six repetitions, in 900 ml dissolution medium maintained at 37 + 0.5 °C. A paddle 139 
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speed of 50 rpm was employed. The tests were conducted under sink conditions. Each 140 
product was placed for 45 minutes into pH 4.5 phosphate buffer (0.05 M KH2PO4) as 141 
the acid stage of the test according to British Pharmacopeia for testing gastric-142 
resistant PPI products (British Pharmacopoeia Commission, 2014). Patients taking 143 
PPI products can have an elevated gastric pH ranging from 3 to 6 with substantial 144 
time period having gastric pH higher than 4.0 (S. Hata et al., 2013; D. C. Metz et al., 145 
2006). Therefore, a higher pH level was used to test gastric-resistance of enteric 146 
coated PPI products than commonly used 0.1 M HCl. After the acid stage, the 147 
products were subsequently transferred into pH 6.8 phosphate buffer (composed of 50 148 
mM KH2PO4 and 23.5 mM NaOH; pH adjusted with 1M HCl / NaOH solutions) or a 149 
pH 6.8 mHanks buffer (F. Liu et al., 2010). The mHanks buffer was adapted from 150 
Hanks’ balanced salt solution (J. H. Hanks, 1975) composed of 136.9 mM NaCl, 5.37 151 
mM KCl, 0.812 mM MgSO4.7H2O, 1.26 mM CaCl2, 0.337 mM Na2HPO4.2H2O, 152 
0.441 mM KH2PO4, 4.17 mM NaHCO3. A sufficient quantity of CO2(g) was purged 153 
into the media to reach pH 6.8 (F. Liu et al., 2010). The pH of the mHanks buffer was 154 
maintained by sparging CO2 into the media during dissolution studies. For products 155 
containing gastro-resistant multiparticulates (pellets and microgranules), after the acid 156 
stage test the pellets or granules were carefully collected using a 125 μm sieve to 157 
avoid any product loss and transferred to the buffer stage test.  158 
 159 
The quantity of active ingredients released from the commercial enteric coated 160 
products was determined using an in-line UV spectrophotometer (Cecil 2020 model, 161 
UK) at the wavelengths of 299, 283 and 299 nm for omeprazole, lansoprazole and 162 
esomeprazole respectively. Data were processed using Icalis software (Icalis Data 163 
Systems Ltd, Berkshire, UK). Drug release lag times (tlag), t80 and release rate were 164 
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calculated for all formulations in pH 6.8 phosphate and mHanks buffers.  The tlag is 165 
defined as the first time point when the percentage cumulative drug release is greater 166 
than 5%. The t80 is the first time point when the percentage cumulative drug release 167 
has reached above 80%. The drug release rate is the slop of the linear plot of 168 
percentage drug release against time.  169 
 170 
Buffer capacity (β) of the buffers used in the dissolution test was measured by adding 171 
aliquots of 0.1M HCl to 100 ml of the buffer until a pH change of 0.5 units. The 172 
measurements were conducted in triplicates. Buffer capacity was then calculated 173 
using Eq.(1).  174 
ߚ ൌ ∆஺஻∆௣ு                                                                                                                       (1)	175 
Where ∆ܣܤ is the small increment in mol/L of the amount of acid added to produce a 176 
pH change of ∆݌ܪ in the buffer.  177 
 178 
The in vitro drug release data was analysed by two-way ANOVA followed by post-179 
hoc analysis by Tukey with 99.8% confidence interval using Univariate General 180 
Linear Model tool in PASW Statistics 21 (SPSS Inc., Illinois, USA).181 
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 182 
Table 1. Commercial PPI products included in the study 183 
 184 
Brand name  Strength  Formulation  Enteric coating  Manufacturer 
Esomeprozole         
 
Nexium  10 mg  Gastro‐resistant granules for oral suspension, sachet 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  AstraZeneca 
Emozul  20 mg  Gastro‐resistant pellet‐enclosed capsule  
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  Consilient Health Ltd 
Actavis  20 mg 
Dispersible tablet containing 
gastro‐resistant pellets 
(MUPS tablet*) 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  Actavis Group PTC 
Lansoprazole         
 
Actavis  15 mg  Gastro‐resistant pellet‐enclosed capsule 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion   Actavis Group PTC 
Almus  15 mg  Gastro‐resistant pellet‐enclosed capsule 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  Zentiva 
Zoton  15 mg 
Oro‐dispersible tablet 
containing gastro‐resistant 
microgranules (MUPS tablet*) 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion; 
polyacrylate dispersion 30% 
Pfiz er 
Omeprazole         
  Actavis  10 mg  Gastro‐resistant pellet‐enclosed capsule 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  Actavis Group PTC 
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Mepradec  10 mg  Tablet enclosed capsule  Hypromellose acetate succinate  Dexcel Pharma Ltd 
Almus  10 mg  Gastro‐resistant pellet‐enclosed capsule 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  Sandoz Ltd 
Losec caps  10 mg  Gastro‐resistant pellet‐enclosed capsule 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  AstraZeneca 
Losec MUPS  10 mg 
Dispersible tablet containing 
gastro‐resistant pellets 
(MUPS tablet*) 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  AstraZeneca 
Mezzopram  10 mg 
Dispersible tablet containing 
gastro‐resistant pellets 
(MUPS tablet*) 
Methacrylic acid – ethyl acrylate 
copolymer (1:1) 30% dispersion  Sandoz Ltd 
  185 
*MUPS: Multiple-Unit Pellet System186 
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3. Results  187 
 188 
Particle sizes of the multiparticulate-based products vary substantially among the 189 
tested preparations (Table 2). The omeprazole product Losec MUPS had smallest 190 
particle size with over 70% particles in the range of 180-250 μm. All pellet-enclosed 191 
capsule formulations had larger particle sizes compared to the tablet forms or sachet 192 
formulations. The majority of pellet-enclosed capsules contained pellets with a 193 
particle size larger than 1mm.  194 
 195 
Table 2. Particle size of multiparticulate products 196 
  
Brand 
name Formulation 
Particle size  
  Sieve method,              μm (% weight) 
Laser diffraction 
(X50), μm 
Esomeprozole    
 Emozul 
Pellet-
enclosed 
capsule 
1400 - 2000 (100%) n/a 
 
Nexium Granules (sachet) n/a 648 
Actavis MUPS tablet 
500 - 710 (21%);      
355 - 500 (75.23%); 
250 - 355 (3.77%) 
494 
Lansoprazole    
 
Actavis 
Pellet-
enclosed 
capsule 
1000 -1400 (83.63%);      
710 - 1000 (16.37%) n/a 
Almus 
Pellet-
enclosed 
capsule 
1000 -1400 (7.65%) 
710 -1000 (92.35%)  n/a 
Zoton 
Oro-
dispersible 
tablet (MUPS 
tablet) 
n/a 352 
Omeprazole    
  12
 
Almus 
Pellet-
enclosed 
capsule 
1400 - 2000 (52.56%);  
1000 - 1400 (45.67%); 
710 - 1000 (1.77%) 
n/a 
Actavis 
Pellet-
enclosed 
capsule 
1400 - 2000 (13.73%);  
1000 - 1400 (86.27%)  n/a 
Losec caps 
Pellet-
enclosed 
capsule 
1400 - 2000 (8.65%); 
1000 - 1400 (91.35%)  n/a 
Mezzopram MUPS tablet 500 - 710 (95.21%); 335 - 500 (4.79%)  n/a 
Losec 
MUPS MUPS tablet 
335 - 500 (5.45%);   
250 - 335 (26.96%); 
180 - 250 (73.04%) 
n/a 
n/a: not applied 197 
 198 
The buffer capacities of the pH 4.5 phosphate buffer (acid stage), pH 6.8 phosphate 199 
buffer and pH 6.8 mHanks buffer were 0.88 ± 0.10, 23.21 ± 0.07 and 3.38 ± 0.15 200 
mmol/L/∆pH respectively. Drug release profiles from commercial products 201 
containing esomeprazole, lansoprazole and omeprazole are presented in Figures 1-3. 202 
For all products tested, a significant difference (p<0.005) was found between the 203 
dissolution profiles of each product in pH 6.8 phosphate buffer and in pH 6.8 mHanks 204 
buffer (Figures 1-3). The dissolution profiles between different brands of the same 205 
active ingredient (esomeprazole, lansoprazole or omeprazole) in pH 6.8 phosphate 206 
buffer did not show significant differences (Figures 1a, 2a and 3a).  In pH 6.8 mHanks 207 
buffer, the dissolution profiles of the three esomeprazole products were found to be 208 
significantly different from each other (p<0.005) (Figure 1b). For lansoprazole 209 
products tested in pH 6.8 mHanks buffer, the dissolution profile of the brand Zoton is 210 
significantly different from the other two brands (Almus and Actavis) (p<0.005); 211 
however, the dissolution profiles of the brands Almus and Actavis did not show a 212 
significant difference (Figure 2b). The dissolution profile of brand Almus containing 213 
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omeprazole in pH 6.8 mHanks buffer did not show a significant difference from the 214 
brands Losec and Mepradec containing the same drug (Figure 3b). All other 215 
dissolution profiles of omeprazole products in pH 6.8 mHanks buffer as shown in 216 
Figure 3b were significantly different from each other (p<0.005). 217 
 218 
 219 
The drug release lag times, t80 and release rates (k) are shown in Tables 3 and 4.  Drug 220 
release from all tested products was immediate (lag times between 5 to 10 minutes) in 221 
pH 6.8 phosphate buffer with t80 ranging from 5.8 ± 2.0 to 37.5 ± 6.1 minutes, 222 
complying pharmacopoeia requirements (e.g. 80% drug release in 45 minutes as 223 
specified in British Pharmacopoeia (British Pharmacopoeia Commission, 2014)).  A 224 
substantial delay in the onset time of drug release (tlag ranging from 20.8 ± 2.0 to 53.3 225 
± 2.6 minutes) was observed in all tested products in pH 6.8 mHanks buffer. 226 
Furthermore, only one product, omeprazole Losec caps, had more than 80% drug 227 
release within 45 minutes (t80 44.2 ± 2.0 minutes). All other enteric coated products 228 
had less than 80% drug release within 45 minutes (t80 ranging from 45.8 ± 2.0 to 92.5 229 
± 5.2 minutes) in pH 6.8 mHanks buffer and therefore failed the pharmacopeia 230 
requirement.  231 
  232 
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Table 3. The tlag (minute), t80 (minute) and release rate (k, % release/minute) from esomeprazole and lansoprazole products in pH 6.8 phosphate 234 
and mHanks buffers. The tlag and t80 are presented as post-acid exposure times (excluding the time period in acid stage).  235 
 236 
  
Esomeprazole  Lansoprazole 
Buffer solution 
(pH 6.8) 
Actavis  Emozul  Nexium  Actavis  Almus  Zoton 
tlag   t80    k   tlag    t80    k   tlag    t80    k   tlag    t80    k   tlag    t80    k   tlag    t80    k  
Phosphate   5.0 ± 0.0 
25.0 ± 
0.0 
4.0 ± 
0.2 
10.0 ± 
0.0 
25.0 ± 
0.0 
4.9 ± 
0.1 
10.0 ± 
0.0 
43.3 ± 
6.1 
2.8 ± 
0.2 
5.0 ± 
0.0 
20.0 ± 
0.0 
3.2 ± 
0.1 
5.0 ± 
0.0 
16.7 ± 
2.6 
6.9 ± 
0.2 
5.0 ± 
0.0 
5.8 ± 
2.0 
17.3 ± 
1.0 
mHanks    21.7 ± 2.6 
60.8 ± 
2.0 
2.5 ± 
0.4 
53.3 ± 
2.6 
75.8 ± 
2.0 
3.3 ± 
0.4 
46.7 ± 
5.2 
75.0 ± 
5.5 
3.3 ± 
0.5 
20.8 ± 
2.0 
51.7 ± 
5.2 
3.0 ± 
0.4 
30.0 ± 
0.0 
47.5 ± 
2.7 
5.4 ± 
0.4 
31.7 ± 
2.6 
56.7 ± 
6.1 
2.9 ± 
0.6 
 237 
 238 
 239 
Table 4. The tlag (minute), t80 (minute) and release rate (% release/minute) from omeprazole products in pH 6.8 phosphate and mHanks buffers. 240 
The tlag and t80 are presented as post-acid exposure times (excluding the time period in acid stage).  241 
 242 
Buffer solution 
(pH 6.8) 
Actavis  Mepradec  Almus  Losec caps  Losec MUPS  Mezzopram 
tlag   t80   k  tlag   t80   k  tlag   t80   k  tlag   t80   k   tlag   t80   k  tlag   t80   k 
Phosphate   5.0 ± 0.0 
25.0 ± 
0.0 
4.1 ± 
0.2 
5.0 ± 
0.0 
20.0 ± 
0.0 
3.6 ± 
0.7 
10.0 ± 
0.0 
20.0 ± 
0.0 
7.2 ± 
0.8 
7.5 ± 
2.7 
12.5 ± 
2.7 
14.7 ± 
0.8 
5.0 ± 
0.0 
31.7 ± 
4.1 
3.0 ± 
0.4 
5.0 ± 
0.0 
37.5 ± 
6.1 
3.3 ± 
0.3 
mHanks    41.7 ± 2.6 
64.2 ± 
2.0 
4.3 ± 
0.2 
30.8 ± 
2.0 
54.2 ± 
6.6 
3.6 ± 
0.7 
30.8 ± 
2.0 
45.8 ± 
2.0 
4.0 ± 
0.6 
27.5 ± 
2.7 
44.2 ± 
2.0 
5.0 ± 
0.5 
35.8 ± 
2.0 
67.5 ± 
5.2 
2.7 ± 
0.7 
21.7 ± 
14.4 
92.5 ± 
5.2 
1.9 ± 
0.1 
 243 
 244 
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4. Discussion 245 
Physiological bicarbonate buffers have been previously proven to be more realistic 246 
dissolution media compared to compendial phosphate buffers and provide better 247 
discrimination between enteric coated drug delivery systems (V. C. Ibekwe et al., 248 
2006; F. Liu et al., 2010). The current study is the first to apply bicarbonate buffer to 249 
compare in vitro dissolution performances of commercially available enteric coated 250 
multiparticulate products targeting to the small intestine. In agreement with previous 251 
reports, compendial pH 6.8 phosphate buffer failed to distinguish dissolution profiles 252 
between different enteric coated multiparticulate PPI products. However, these 253 
products showed significantly different dissolution profiles in the pH 6.8 mHanks 254 
bicarbonate media in most cases. In addition, drug release from the enteric coated 255 
products was immediate and rapid in pH 6.8 phosphate buffer. However, marked 256 
delay in drug release onset time was noted in the more realistic pH 6.8 mHanks buffer 257 
which simulates closely the human jejunal fluid. For most products tested, except 258 
Nexium (esomeprazole), Actavis (omeprazole) and Mepradec (omeprazole), drug 259 
release rates (k) were slower in the bicarbonate buffer compared to the phosphate 260 
buffer.  261 
 262 
Drug release from enteric coated products is determined by the dissolution of the 263 
carboxylic acid polymers used for the coating which, in turn, is determined by the 264 
ionization of the polymers in aqueous solutions. The presence of various ions and 265 
buffer species in the dissolution media profoundly influences the ionization rate of the 266 
polymer (J. Spitael and R. Kinget, 1977).  According to Bronsted catalysis law, the 267 
dissolution rate of a carboxylic acid polymer is directly proportional to the pKa of the 268 
buffer specie in the solution (J. Spitael et al., 1980).  Buffer capacity of the salt which 269 
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links to its pKa also plays a role in the acidic polymer dissolution (E. Shek, 1978). In 270 
addition, the composition and strength of other ions present in the solution have an 271 
effect on the polymer dissociation (F. Liu et al., 2010). The pKa and buffer capacity 272 
are distinct between pH 6.8 phosphate buffer (pKa 7.19, buffer capacity 23.1 ± 0.3 273 
mmol/L/∆pH) and pH 6.8 bicarbonate buffer (pKa 6.31, buffer capacity 3.1 ± 0.2 274 
mmol/L/∆pH) (F. Liu et al., 2010). The ionic composition and strength of the two 275 
dissolution media are also remarkably different. All these factors explain the 276 
differences in dissolution profiles of enteric coated systems in the phosphate buffer 277 
and the bicarbonate buffer.  278 
 279 
Drug release from a core surrounded by an enteric coating is governed by two 280 
dynamic and simultaneous processes, the dissolution of the enteric polymer and the 281 
diffusion of the drug through the dissolving polymer layer.  Ozturk et al (1988) 282 
described that as the enteric polymer dissolves, the thickness of the polymer layer 283 
reduces and the release rate of the drug increases over time. For enteric coated tablets, 284 
tablet disintegration is presumed to coincide with 95% completion of the polymer 285 
dissolution and the subsequent drug release is dependent on the dissolution of the 286 
drug from the disintegrated tablet core (S. S. Ozturk et al., 1988). The enteric coated 287 
multiparticulates used in this study are based on microcrystalline cellulose or sugar 288 
spheres as core materials which do not show typical disintegration as shown in tablets. 289 
It can be speculated that the onset time of drug release from coated pellets is mostly 290 
affected by the dissolution rate of the enteric polymer in the aqueous medium. The 291 
drug release rate (k) at the linear plot of the dissolution graph and the complete 292 
release of the drug can be affected by both the dissolution of the polymer and the 293 
release of the drug from the core.  294 
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 295 
Previous reports have compared the dissolution of enteric coated systems applying 296 
different enteric polymers in bicarbonate buffer (F. Liu et al., 2010). Their distinct 297 
dissolution profiles were explained by differences in the polymer pKa and chemical 298 
structure, such as the aqueous solubility of the polymer backbones and the degree of 299 
substitution (M. Davis et al., 1986; S. S. Ozturk et al., 1988). However, the 300 
commercial enteric coated products used in this study are all (except Mepradec) based 301 
on the same enteric polymer, methacrylic acid – ethyl acrylate copolymer (1:1) 30% 302 
aqueous dispersion (commercially available as Eudragit® L 30D-55), according to 303 
their Summary of Product Characteristics (SPC) (Datapharm Communications 304 
Limited, 2013). The enteric polymer used in Mepradec (omeprazole) is hypromellose 305 
acetate succinate (HPMCAS) which is also commonly used in aqueous based coating 306 
systems. Previous study showed that when HPMCAS was applied at a coating level 307 
providing sufficient acid-resistance, drug release from coated tablets was comparable 308 
to that from tablets coated with Eudragit® L 30D-55 in bicarbonate buffer (F. Liu et 309 
al., 2010).  As such, the difference in drug release between the products investigated 310 
in this study indicates that formulation factors other than the enteric polymer could 311 
play a role in determining the dissolution of the coating and the resultant drug release.  312 
 313 
Particle size of the multiparticulate-based products ranges from around 250 µm to 314 
2000 µm, which might affect the dissolution of the polymer and drug release due to 315 
available surface area in contact with aqueous media. The rank order of drug release 316 
for esomeprazole products (Actavis < Nexium < Emozul) in pH 6.8 mHanks buffer 317 
correlated well with their particle sizes (Actavis < Nexium < Emozul); the product 318 
with the smallest particle size showed fastest drug release.  The rank order was 319 
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obtained by comparing the drug release onset time between the products. If two 320 
products have the same onset time, the release rate was then compared. This 321 
relationship between drug release rank order and particle size was not observed for 322 
lansoprazole and omeprazole products. The rank order of drug release for omeprazole 323 
products is Mezzopram < Losec Caps < Almus < Mepradec (tablet) < Losec MUPS < 324 
Actavis, which shows no relationship with the rank order of particle size, Losec 325 
MUPS < Mezzopram < Actavis ≈ Losec Caps ≈ Almus < Mepradec (tablet). For 326 
lansoprazole products, the brand Zoton showed slowest drug release profile in pH 6.8 327 
mHanks buffer despite that it has the smallest particle size. Zoton (lansoprazole) is an 328 
oro-dispersible tablet containing gastro-resistant microgranules. The SPC of this 329 
product suggests that other than methacrylic acid copolymer a second polymer 330 
“polyacrylate dispersion 30 percent” was used for the coating (Datapharm 331 
Communications Limited, 2013). Although the grade of the polyacrylate polymer was 332 
not specified, it has been reported that ethyl acrylate-methyl methacrylate copolymer 333 
30% dispersion (Eudragit® NE 30D) was used in addition to Eudragit® L 30D-55 in 334 
developing gastric-resistant PPI formulations (T. Shimizu et al., 2003; R. N. Tirpude 335 
and P. K. Puranik, 2011). Eudragit® NE 30D is insoluble in water independent of pH 336 
and is used for sustained release film coatings. This polymer has a very low glass 337 
transition temperature of 13°C and can be used in polymer blends with other acrylic 338 
polymers to decrease glass transition temperature and thus increase film flexibility (Y. 339 
El-Malah and S. Nazzal, 2008; S. Kucera et al., 2009). This is beneficial during the 340 
compression of gastric-resistant microgranules into oro-dispersible tablets to prevent 341 
film cracking. However, the presence of the insoluble Eudragit® NE 30D in the 342 
enteric coating could decrease drug release rate and may be the reason for the slower 343 
release as observed in Zoton compared to other lansoprazole products.  344 
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 345 
It is interesting to note that the omeprazole product Losec Caps showed significantly 346 
faster drug release in pH 6.8 mHanks buffer than Losec MUPS (omeprazole) despite 347 
having larger particle size and being produced by the same manufacturer. Losec 348 
MUPS tablet comprise omeprazole enteric coated microgranules which are 349 
compressed into orally disintegrating tablets. To ensure that the coated microgranules 350 
are able to withstand the compression into tablets, it is likely that thicker coatings or 351 
extra coating layers are required to maintain sufficient gastric-resistance. It has been 352 
reported that the enteric-coated microgranules in lansoprazole orally disintegrating 353 
tablets comprise seven layers, a core, an under-coating layer, three layers of enteric-354 
coating and an over-coating layer to improve stability, reduce damage during 355 
compression and neutralize the taste of the microgranules (F. Baldi and P. 356 
Malfertheiner, 2003). This may explain the longer onset time for drug release and 357 
slower drug release rate in mHanks buffer from Losec MUPS compared to Losec 358 
Caps.  359 
 360 
Coating thickness could be a factor affecting drug release rate from different enteric 361 
coated products. When methacrylic acid copolymer was applied onto prednisolone-362 
loaded pellets (1mm in diameter), dissolution was significantly faster from pellets 363 
obtained 15% weight gain from the coating compared to those with 20% weight gain 364 
(data not shown). The inclusion of other formulation additives could also influence 365 
drug release. For example, the type and amount of plasticizers used in the coating 366 
formulation affect the mechanical properties of the coating during dissolution and the 367 
drug release rate (H. M. Fadda et al., 2008). It is likely that drug release from the final 368 
coated product is determined by the interplay of the different factors. An investigation 369 
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of the individual contribution to drug release by these factors would be of interest for 370 
future research.  371 
 372 
Significant lag times in drug release from enteric coated tablets in physiological 373 
bicarbonate buffers were reported previously, which correlates to the reported delay in 374 
disintegration times of enteric coated tablets in the human intestine (C. Bogentoft et 375 
al., 1984; J. P. Ebel et al., 1993; F. Liu et al., 2010). Results in this study show that a 376 
similar delay in drug release occurred in bicarbonate buffer from enteric coated 377 
multiparticulate PPI products, intended for use in patients who are unable to swallow 378 
intact tablets especially children, older patients and patients with swallowing 379 
difficulties. The in vivo dissolution of enteric coatings and the resultant drug release 380 
from coated products are determined by physiological factors of the gastrointestinal 381 
tract such as gastric emptying and the pH, volume, ionic composition, and buffer 382 
capacity of the intestinal fluids. Currently there is a lack of knowledge in these 383 
physiological factors in children especially in the very young age groups such as 384 
neonates and infants (H. K. Batchelor et al., 2014). For example, small intestinal pH 385 
was reported to be comparable to adults in older children (8-14 years old); however, 386 
no data available for younger age groups (J. L. Kaye, 2011). It is therefore unclear 387 
how these physiological factors affect the dissolution of enteric coated products in 388 
children. However, the available fluid volume for dissolution is significantly lower in 389 
the intestine of young children than in that of adults (H. K. Batchelor et al., 2013). It 390 
can be speculated that the observed delay in drug release from these products in 391 
mHanks buffer is likely to result in delayed dissolution in vivo in paediatric patients. 392 
There are indeed reports of unabsorbed enteric coated omeprazole pellets in the 393 
gastric contents or stool of infants (C. Tuleu et al., 2008). A study reported that half of 394 
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the critically ill pediatric patients who received nasogastric administration of 395 
omeprazole suspensions either did not respond to the treatment or required significant 396 
dose titration to achieve gastric acid suppression (J. A. Haizlip et al., 2005).  397 
 398 
The potential delay in in vivo drug release from enteric-coated PPI products reflects 399 
literature reports on the slow exertion of their maximum antisecretory effects.  Suzuki 400 
et al. reported that it took significantly longer time to reach a gastric pH of 3 401 
following lansoprazole administration (3.75 ± 0.48 hours) compared to that following 402 
famotidine administration (2.24 ± 0.51 hours) (T. Suzuki et al., 2008). In another 403 
study, the mean gastric pH increased to above 4 within 15 minutes after the 404 
administration of immediate release omeprazole (containing non-enteric coated 405 
omeprazole stabilised using sodium bicarbonate) (P. O. Katz et al., 2007). In contrast, 406 
mean gastric pH did not reach 4 until 3 hours after the administration of enteric coated 407 
esomeprazole and more than 5 hours after the dosing of enteric coated lansoprazole. 408 
This is in agreement with reported delays in in vivo drug absorption from enteric 409 
coated PPI products. Boussery et al. showed that the time to reach maximum plasma 410 
drug concentration (tmax) was 0.57 ± 0.16 and 2.36 ± 1.74 hours for immediate release 411 
omeprazole suspensions and enteric coated omeprazole MUPS tablets respectively in 412 
patients with severe neurodevelopmental problems (K. Boussery et al., 2011). In 413 
addition, the MUPS tablets showed high inter-individual variation in reaching tmax 414 
(ranging from 1 to 6 hours). Similar results were shown in another study conducted in 415 
healthy volunteers in both fasted and fed conditions (Z. Liu et al., 2013). This is better 416 
reflected by the in vitro drug release results in pH 6.8 mHanks buffer than phosphate 417 
buffer, as the former reveals the difference in drug release profiles between the tested 418 
PPI products as well as the variation in drug release in the six dissolution test 419 
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repetitions of the same product (as shown by the higher standard deviation in tlag, t80 420 
and release rate).  421 
 422 
To gain an understanding of the correlation between the in vitro dissolution results 423 
and in vivo absorption parameters of enteric coated products, one must take into 424 
account of gastric emptying time of these preparations. Unlike tablets, pellets empty 425 
from the stomach in consecutive portions over a period of time (J. M. Newton, 2010). 426 
Marked intra- and inter-individual variability in the gastric emptying kinetics of 427 
pellets has been reported even under fasting conditions, with emptying time varying 428 
from 15 minutes to more than 3 hours (I. Locatelli et al., 2009). Locatelli et al have 429 
attempted to develop a mathematical model to described gastric emptying of pellets 430 
under fasting conditions and have suggested an overall mean value of approximately 431 
40 minutes to guide the development of in vitro dissolution methods (I. Locatelli et 432 
al., 2009). Since previously reported pharmacokinetic profiles of enteric coated PPI 433 
multiparticulate products do not provide gastric emptying values, an attempt is made 434 
to add the suggested average gastric emptying time to the t80 of drug release in pH 6.8 435 
phosphate and mHanks buffer and compared to reported in vivo tmax values under 436 
fasting conditions. The reported in vivo tmax values for enteric coated esomeprazole 437 
multiparticulate preparations range from 1.3 to 2.0 hours (N. Bladh et al., 2007; M. B. 438 
Sostek et al., 2003). The in vitro drug release t80 values (including a mean gastric 439 
emptying time of 40 minutes) of esomeprazole products are 1.1-1.4 and 1.7-1.9 hours 440 
in pH 6.8 phosphate buffer and mHanks buffer respectively. For lansoprazole 441 
products, the reported in vivo tmax values are in the range of 1.6 to1.9 hours (J. W. 442 
Freston et al., 2003; K. Iwasaki et al., 2004) and the in vitro t80 values are 0.8-1.0 and 443 
1.5-1.6 hours in pH 6.8 phosphate buffer and mHanks buffer respectively. The 444 
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reported in vivo tmax values for omeprazole products range from 1.9 to 4.0 hours (K. 445 
Boussery et al., 2011; S. Karim et al., 2014; Z. Liu et al., 2013) and the in vitro t80 446 
values are 0.9-1.3 and 1.2-2.2 hours in pH 6.8 phosphate buffer and mHanks buffer 447 
respectively. A closer relationship between the t80 values in mHanks buffer and the in 448 
vivo tmax can be observed compared to phosphate buffer, indicating a potential for 449 
improved in vitro-in vivo correlation. It needs to be noted that using an average gastric 450 
emptying time overlooks the intra- and inter- individual variations in gastric emptying 451 
of pellets and oversimplifies the complex nature of the process. A better evaluation in 452 
in vitro- in vivo correlation of these enteric-coated multiparticulate formulations can 453 
be achieved using pharmacoscintigraphy studies taking into account of gastric 454 
emptying times of individual pharmacokinetic profiles.  455 
 456 
Dynamic dissolution media based on bicarbonate buffers were repo rted recently 457 
which resemble the aboral pH changes in the intestine (G. Garbacz et al., 2014; H. A. 458 
Merchant et al., 2014). An average increase in drug release lag time of about 10 459 
minutes was observed from enteric coated formulations in the dynamic dissolution 460 
system compared to the static bicarbonate buffer used in this study. Although it is 461 
apparent that the dissolution testing under dynamic pH change mode would reflect 462 
better the pH gradients in the human intestine, in vivo such real-time pH profile varies 463 
significantly inter- and intra-individually. It is impractical to echo this variation even 464 
using the dynamic dissolution system. Furthermore, there is not sufficient data 465 
available in the pH values relevant to intestinal transit time in children or older people 466 
to support the design of a meaningful dynamic pH change for testing these products. 467 
Therefore, the static pH 6.8 bicarbonate buffer is used in this study and it was able to 468 
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discriminate between different enteric coated commercial multiparticulate PPI 469 
products and revealed their inherent shortcomings of delayed drug release.  470 
   471 
4. Conclusions 472 
Significant delay in drug release was identified from commercial enteric coated PPI 473 
products intended for paediatric and geriatric use in pH 6.8 physiological bicarbonate 474 
(mHanks) buffer. This buffer was able to discriminate between the different enteric 475 
coated multiparticulate preparations, providing a rank dissolution order. This 476 
knowledge reflects literature reports on the delay in absorption and onset of 477 
antisecretory effects of these products and is likely to improve in vitro-in vivo 478 
correlations. The vitro dissolution using the bicarbonate buffer can be a useful tool in 479 
the rational design of enteric coated PPI products to meet the needs of different 480 
patient populations. 481 
 482 
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Figure 1. Drug release from esomeprazole enteric‐coated products in pH 4.5 PBS (45 minutes), and subsequent pH 6.8 phosphate buffer (a) and mHanks 489 
buffer (b) 490 
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a)                                                                                                            (b) 497 
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 499 
 500 
Figure 2. Drug release from lansoprazole enteric‐coated products in pH 4.5 PBS (45 minutes), and subsequent pH 6.8 phosphate buffer (a) and mHanks 501 
buffer (b) 502 
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(a)                                                                                                                           (b) 505 
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 507 
 508 
Figure 3. Drug release from omeprazole enteric‐coated products in pH 4.5 PBS (45 minutes), and subsequent pH 6.8 phosphate buffer (a) and mHanks 509 
buffer (b) 510 
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